ИНФОРМАЦИОННОЕ ПИСЬМО
Аннотация
Список литературы
1. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular,events. N Eng J Med. Published online 31 Mar,2008.
2. The Heart Outcomes Prevention Evaluation Study,Investigators. Effects of an angiotensin-convertingenzyme,inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145–53.
3. The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/ Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) trials Am Heart J 2004; 148(1):52–61.
4. Bakris G, et al. Influence of glycemic control on proteinuria in patients with type 2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial. 67th Sci Sess of the American Diabetes Association (ADA), Chicago, 22 – 26 Jun 2007 (Poster) 2007.
5. Williams B, et al. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMAI). J Hypertens 2006; 24:193–200.
6. Lacourciиre Y, et al. A multicenter, 14-weeks study of telmisartan and ramipril in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19:104–12
7. World Health Organization, Fact Sheet 317: Cardiovascular Diseases February 2007. http://www. who.int/mediacentre/factsheets/fs317/en/index.html (Accessed March 2008)
8. Murray CJL, Lopez AD. eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge; Harvard University Press 2001.
9. Primary Prevention of Ischemic Stroke. A Guideline From the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37:1583–1633.
Рецензия
Для цитирования:
ИНФОРМАЦИОННОЕ ПИСЬМО. Кардиоваскулярная терапия и профилактика. 2008;7(5):125-128.